Partial Reprogramming
Transient expression of Yamanaka factors (OSKM) to reverse cellular aging without full dedifferentiation.
Evidence Summary
Partial reprogramming — transient, cyclic expression of Yamanaka factors (typically OSK, omitting c-Myc) — remains one of the most active areas of longevity research, but all efficacy data to date are preclinical (cell and animal models); there are no human anti-aging trials. A peer-reviewed 2024 study in Cellular Reprogramming (Cano Macip et al.) reported that systemic AAV-delivered OSK gene therapy in ~124-week-old mice (roughly 77 human years) approximately doubled median remaining lifespan (18.5 vs 8.86 weeks in controls, a ~109% increase) and lowered a frailty index, with no tumors observed over the study. A 2025 Cell paper (Lu et al.) identified an age- and disease-associated "mesenchymal drift" — a loss of tissue identity — that partial reprogramming reverses before any loss of cell identity, providing a mechanistic rationale. Tissue-specific benefits were reported across 2025-2026 work in the brain (a P301S tauopathy model of Alzheimer's disease improved memory and reduced tau pathology), endothelium/cardiovascular system (restored blood flow after hind-limb ischemia in aged mice), retina, muscle and liver. Balancing this, a 2026 Aging Cell study found that small-molecule ("chemical") reprogramming cocktails can cause dose-dependent toxicity in mice, underscoring a narrow therapeutic window. Well-funded programs (Altos Labs, Retro Biosciences, Turn Biotechnologies, Rejuvenate Bio, NewLimit) continue to advance the approach, but human application remains investigational and years away. Educational information only.
Evidence Scale
Mechanism of Action
Brief, pulsed expression of reprogramming factors (Oct4, Sox2, Klf4, with c-Myc often omitted for safety) resets age-associated epigenetic marks — DNA methylation patterns and repressive histone marks such as H3K9me3 — shifting the cellular epigenome toward a more youthful state while preserving somatic cell identity (stopping short of dedifferentiation to pluripotency). Recent work frames one key beneficial effect as reversal of "mesenchymal drift," the age-related loss of tissue identity. Cyclic dosing and tissue-targeted delivery are used to capture rejuvenation while avoiding the teratoma and organ-failure risks of full reprogramming.
Who Is This For?
Experimental/research phase. Potentially transformative but years from clinical application.
Protocol & Dosing
Dose
Still in research phase. No established human protocols.
Frequency
Unknown
Duration
Experimental
Protocol Summary
Strictly experimental. Delivery approaches under study include AAV gene therapy, mRNA/lipid-nanoparticle systems, CRISPR-activation, and small-molecule ("chemical") cocktails, with cyclic or transient dosing to limit dedifferentiation. No validated human anti-aging protocol, dose or safety window exists. Not offered clinically at Peak Human.
Interactions & Precautions
Contraindications
- Not applicable - experimental
Potential Risks
- •Cancer risk
- •Teratoma formation (full)
- •Unknown long-term effects
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
The most fundamentally exciting longevity research area — but preclinical: efficacy is demonstrated in mice and cells, not people, and 2026 data highlight real dose-dependent toxicity with some chemical approaches. Programs to watch: Altos Labs, Retro Biosciences, Turn Biotechnologies, Rejuvenate Bio, NewLimit. Educational overview only; not a therapy Peak Human offers.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Latest Evidence
2024–2026: what the preclinical evidence now shows
Partial reprogramming uses brief, cyclic expression of Yamanaka factors (usually OSK, omitting c-Myc) to reset age-related epigenetic marks while keeping a cell's identity intact. In a peer-reviewed 2024 study in Cellular Reprogramming, systemic AAV-delivered OSK gene therapy in ~124-week-old mice (roughly 77 human years) approximately doubled median remaining lifespan — 18.5 versus 8.86 weeks in controls, about a 109% increase — alongside a lower frailty index and no tumors observed over the study. A 2025 paper in Cell identified an age- and disease-associated "mesenchymal drift," a loss of tissue identity that partial reprogramming reverses before any loss of cell identity, giving the approach a clearer mechanism.
Tissue-specific benefits were reported across 2025–2026 work: memory improved and tau pathology fell in a P301S mouse model of Alzheimer's disease; transient reprogramming restored blood flow after hind-limb ischemia in aged mice; and rejuvenation signals were seen in the retina, muscle and liver. Balancing the enthusiasm, a 2026 Aging Cell study found small-molecule ("chemical") reprogramming cocktails can cause dose-dependent toxicity in mice, underscoring a narrow therapeutic window.
Important context: every efficacy result here is preclinical — in cells and animals, not people. There are no human anti-aging trials of partial reprogramming, no validated dose or safety window, and the main risks (uncontrolled reprogramming, teratoma formation, organ dysfunction) are why the field relies on cyclic dosing and targeted delivery. Well-funded programs (Altos Labs, Retro Biosciences, Turn Biotechnologies, Rejuvenate Bio, NewLimit) are advancing the work, but human application remains investigational and years away. Peak Human does not offer this as a therapy. Educational information, not medical advice.
Preclinical · aged mice (~124 weeks) · ~109% increase
Median remaining lifespan after OSK gene therapy
Source: Cano Macip et al., Cellular Reprogramming, 2024 — systemic AAV-delivered OSK gene therapy in ~124-week-old mice (≈77 human years), cyclic induction. Bars show median remaining lifespan vs doxycycline-only controls. Preclinical (mouse) data; not established in humans.
Related on Peak Human
Stem Cell Therapy
A related regenerative approach in the Database, with a clinical evidence base.
Gene Therapy
The delivery platform behind AAV-based reprogramming experiments.
Exosome Therapy
Another emerging cellular-rejuvenation strategy under active study.
Diagnostic Testing
Epigenetic (biological-age) clocks are how rejuvenation is measured.
Longevity Research Insider
Weekly review of new longevity research.
Key references: Gene therapy–mediated partial reprogramming extends lifespan & reverses age-related changes in aged mice — Cellular Reprogramming (2024) · Prevalent mesenchymal drift in aging & disease is reversed by partial reprogramming — Cell (2025) · Partial reprogramming improves pathology in a tauopathy model of Alzheimer's disease — Progress in Neurobiology (2025) · Functional rejuvenation of endothelial cell aging by transient reprogramming — Basic Research in Cardiology (2026) · In vivo chemical reprogramming & toxic lipid-droplet accumulation hindering rejuvenation — Aging Cell (2026)
Cost & Access
Cost Range
N/A
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation